Diarrhea – Pipeline Review, 2019

Diarrhea is characterized by loose, abnormal, and frequent bowel movement and is one of the most common health problems. According to the World Gastroenterology Organization, an estimated 2 billion cases of diarrhea are recorded each year worldwide with approximately 1.9 million children below five years of age dying due to diarrhea. There are many known causes of diarrhea, namely due to viral, bacterial, or parasitic infections. Some of the serious diseases that cause diarrhea include, inflammatory bowel disease like Crohn's disease, Celiac disease, cancer, among others.

The primary line of treatment of diarrhea includes rehydration with oral rehydration solution or salts (ORS). Over the counter antidiarrheal medications that comprise of Imodium and Loperamide, which are antimotility drugs are usually prescribed to decrease stool passage. The patient is prescribed medications for the treatment of the infection once the cause of diarrhea is diagnosed.

Several research organizations and governments institutes combined with pharmaceutical companies are conducting clinical trials to understand various therapeutic modes to treat and prevent diarrhea. For instance, Boston Pharmaceuticals is studying the safety, tolerability, and efficacy of BOS-589 in treatment of diarrhea caused by Irritable Bowel Syndrome (IBS-D) and is currently in phase 2 clinical trial.

As of 2018, approximately 60% of the pipeline candidates for diarrhea are in the phase-2 and phase-3 clinical stage. More than half of the studies are sponsored by research institutes and government organizations.

Report Description

The report on ‘Diarrhea – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for diarrhea. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for diarrhea.

The report on ‘Diarrhea – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for diarrhea


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for diarrhea


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary